AestheticsFeatured ArticlesPhotoprotectionSkin of Color

Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals

By September 9, 2020September 14th, 2020No Comments

Featured Article

Featured Article

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Read more

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Hawasatu Dumbuya PhD, Pearl E Grimes MD, Stephen Lynch PhD, Kalli Ji PhD, Manisha Brahmachary PhD, Qian Zheng Md PhD, Charbel Bouez PhD, Janet Wangari-Talbot PhD

 

 

Visible light (400–700nm), which contributes to 45% of solar radiation, contributes to skin darkening and worsening of dyschromias, particularly in individuals with Fitzpatrick skin phototypes III and higher.

The pathogenesis of melasma is incompletely understood, which poses a challenge for disease management. Causative factors include genetics, ultraviolet (UV) radiation, cosmetics, pregnancy, hormonal therapy, phototoxic drugs, and various medications.

Currently, sunscreens provide limited protection against that spectrum. Due to their capabilities in absorbing, scattering, and reflecting visible light, topical products containing pigments and/or metal oxides can provide additional photoprotection.

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen. Expert grading and colorimetry demonstrated that the iron-oxide containing formulations significantly protected against visible light-induced pigmentation compared to untreated skin or mineral SPF 50+ sunscreen in Fitzpatrick IV individuals.

Read Full Article Now
Article Cited in this Post

Open Access Articles

The Journal of Drugs in Dermatology (JDD) presents Open Access content, unrestricted access to our original articles, award-winning case studies, clinical trial reviews and clearance updates, drugs and devices, and special content geared toward medical residents and other allied health professionals.
Articles are reviewed by the Editorial Board of renowned experts, from key opinion leaders to well-known clinicians. View our open-access dermatology articles now.
View All Open Access Articles

You May Also Like

Journal of Drugs in Dermatology JDD Article about Amelioration of Dominant Dystrophic Epidermolysis Bullosa Ulceration by Combination Gentian Violet and Trichloroacetic Acid Therapy

Amelioration of Dominant Dystrophic Epidermolysis Bullosa Ulceration by Combination Gentian Violet and Trichloroacetic Acid Therapy

| Case Reports, Featured Articles, Latest News | No Comments
Case report: six weeks of gentian violet and trichloroacetic acid peel produced marked healing in dominant dystrophic epidermolysis bullosa with minimal discomfort The February 2026 JDD issue features a case…
Journal of Drugs in Dermatology JDD Article about Combined Use of Relabotulinum Toxin A and NASHA Gel Skinbooster for Rejuvenation of the Upper Third of the Face

Combined Use of Relabotulinum Toxin A and NASHA Gel Skinbooster for Rejuvenation of the Upper Third of the Face

| Aesthetics, Featured Articles, Latest News | No Comments
Combined Relabotulinum Toxin A frontalis modulation with NASHA™ gel skinboosters for the temples yields natural‑looking wrinkle softening and lasting skin quality gains beyond six months A preliminary clinical series tested…
Journal of Drugs in Dermatology JDD Article about Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges

Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges

| Aesthetics, Featured Articles, Latest News | No Comments
From the Vault: Review of the last decade finds biological rationale for skin and hair benefits, yet no FDA approvals and major gaps in standardization and clinical data Dive into…

Leave a Reply